Clinical Trial Update: A Safety And Efficacy Study Of ALG-1001 In Human Subjects With Wet Age-Related Macular Degeneration [Phase 1, Phase 2]

View source ↗

Summary

A combined Phase 1/2 trial evaluating ALG-1001 for safety and efficacy in wet age-related macular degeneration has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• ALG-1001

Snippet

Sponsor: Allegro Ophthalmics, LLC | Conditions: Macular Degeneration | Phase 1, Phase 2 | Status: COMPLETED